Wird geladen...
A phase I study of TAS‐205 in patients with Duchenne muscular dystrophy
OBJECTIVE: Currently, the only approved standard Duchenne muscular dystrophy (DMD) treatment in Japan is oral steroids, which have various disadvantages. Previous work has suggested that hematopoietic‐type prostaglandin D synthase (HPGDS), involved in production of the inflammatory mediator prostagl...
Gespeichert in:
| Veröffentlicht in: | Ann Clin Transl Neurol |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
John Wiley and Sons Inc.
2018
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6243382/ https://ncbi.nlm.nih.gov/pubmed/30480028 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acn3.651 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|